Skip to main content
SpringerLink
Log in

Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer with a Focus on Breast Cancer

  • Chapter
  • First Online:
Antibody-Drug Conjugates and Immunotoxins

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Overexpression of human epidermal growth factor receptor type 2 (HER2; neu; ErbB2) is an important histopathologic feature in a variety of human solid tumors. HER2 is a member of the type I receptor tyrosine kinase family that also includes epidermal growth factor receptor (EGFR, HER1, ERB1), HER3 (ErbB3), and HER4 (ErbB4). HER2 serves as a coreceptor in the dimerization and subsequent activation of the other members of the HER receptors, notably HER3, which forms the major oncologic unit in a subset of breast cancer. HER2 overexpression occurs in 15–20 % of all breast cancers and is associated with poor prognosis without treatment [1, 2]. Biologically, HER2 overexpression has been shown to have important functions in malignant transformation and/or progression of tumors and is associated with decreased response to endocrine therapy. Although HER2 overexpression has been most extensively studied in the context of breast cancer, it has also been observed in other cancers including gastric, ovarian, and pancreatic cancer [3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165–184

    PubMed  Google Scholar 

  2. Dawood S, Broglio K, Buzdar AU et al (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28:92–98

    Article  PubMed  CAS  Google Scholar 

  3. Galsky MD, Von Hoff DD, Neubauer M et al (2012) Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs 30(2):695–701. doi:10.1007/s10637-010-9541-0

    Article  PubMed  CAS  Google Scholar 

  4. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  PubMed  CAS  Google Scholar 

  5. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684

    Article  PubMed  CAS  Google Scholar 

  6. Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4247–4250

    Article  Google Scholar 

  7. Trastuzumab (Herceptin®) Investigator Brochure, Genentech, Inc., South San Francisco, CA, July 2007

    Google Scholar 

  8. Lapatinib (Tykerb®) Product Insert, GlaxoSmithKline, 2008

    Google Scholar 

  9. Johnston S, Pippen J, Pvot X et al (2009) Lapatinib combined with Letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538–5546

    Article  PubMed  CAS  Google Scholar 

  10. Clinicaltrials.gov identifier numbers NCT00526669 and NCT00486954

    Google Scholar 

  11. Spector NL, Xia W, Burris H 3rd et al (2005) Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23:2502–2512

    Article  PubMed  CAS  Google Scholar 

  12. Krop I, Beeram M, Modi S et al (2010) A phase I study of trastuzumab-DM1, a HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2+ metastatic breast cancer. J Clin Oncol 28:2698–2704

    Article  PubMed  CAS  Google Scholar 

  13. Remillard S, Rebhun LI, Howie GS, Kupchan SM (1975) Antimitotic activity of the potent tumor inhibitor maytansine. Science 189:1002–1005

    Article  PubMed  CAS  Google Scholar 

  14. Cassady JM, Chan KK, Floss HG, Leistner E (2004) Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull 52:1–26

    Article  PubMed  CAS  Google Scholar 

  15. Widdison WC et al (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49:4392–4408

    Article  PubMed  CAS  Google Scholar 

  16. Data-on-file, Genentech, Inc., South San Francisco, CA, July 2007

    Google Scholar 

  17. Lewis-Phillips GD, Li G, Dugger DL (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 6:9280–9290

    Article  Google Scholar 

  18. Junttila T, Fields C, G. Li, et al (2008) Trastuzumab-mertansine (T-DM1) retains all the mechanisms of action (MOA) of trastuzumab and is effective in combination with docetaxel. European Organization for Research and Treatment of Cancer Annual Meeting. Abstract #515, 2008

    Google Scholar 

  19. Younes A, Bartlett NL, Leonard JP et al (2010) Brentuximab Vedotin (SGN-35) for relapsed CD30-positive lymphomas. NEJM 363:1812–1821

    Article  PubMed  CAS  Google Scholar 

  20. Austin CD, De Maziere AM, Pisacane PI et al (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15:5268–5282

    Article  PubMed  CAS  Google Scholar 

  21. Austin CD, Wen X, Gazzard L et al (2005) Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. PNAS 102:17987–17992

    Article  PubMed  CAS  Google Scholar 

  22. Shen B-Q, Bumbaca D, Saad O et al (2011) Metabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism [Poster PIII-72]. Clin Pharmacol Ther 89(Suppl 1):S90

    Google Scholar 

  23. Dieras V, Harbeck N, Albain K et al (2010) A phase Ib/II trial of trastuzumab-DM1 with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results [abstract P3-14-01]. Cancer Res 70(Suppl 2):291s

    Google Scholar 

  24. Krop IE, Modi S, Elias A et al (2010) A dose-escalation study of trastuzumab-DM1 (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive, locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen. Abstract P3-14-10. Cancer Res 70(Suppl 2):295s

    Google Scholar 

  25. Holden SN, Beeram M, Krop IE, et al (2008) A phase I study of weekly dosing of trastuzumab-DM1 in patients with advanced HER2+ breast cancer. J Clin Oncol 26(Suppl): abstract 1029

    Google Scholar 

  26. Burris HA, Rugo HS, Vukelja SA et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398–405

    Article  PubMed  CAS  Google Scholar 

  27. Krop I, LoRusso P, Miller KD, et al (2010) A phase 2 study of the HER2 antibody-drug conjugate trastuzumab-DM1 (T-DM1) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab, lapatinib, and chemotherapy [abstract 2770]. Presented at 35th ESMO Congress, 8–12 October 2010, Milan, Italy

    Google Scholar 

  28. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  29. Wolff AC, Hammond M, Schwartz J et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18–43

    PubMed  CAS  Google Scholar 

  30. Press MF, Sauter G, Bernstein L et al (2005) Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11:6598–6607

    Article  PubMed  CAS  Google Scholar 

  31. LoRusso P et al (2010) Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy, Abstract 1016. J Clin Oncol 28 15s: 118s

    Google Scholar 

  32. Tolcher AW, Ochoa L, Hammond LA et al (2003) Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 21:211–222

    Article  PubMed  CAS  Google Scholar 

  33. Ewer SM, Ewer MS (2008) Cardiotoxicity profile of trastuzumab. Drug Saf 31:459–467

    Article  PubMed  CAS  Google Scholar 

  34. Lu D, Gupta M, Wang B, et al (2011) An integrated population pharmacokinetic model for a first-in-class HER2 targeted antibody-drug conjugate trastuzumab emtansine (T-Dm1): simultaneous modeling of T-DM1 and total trastuzumab pharmacokinetics in heavily pretreated HER2-positive metastatic breast cancer patients. Presented at The American Society of Clinical Pharmacology and Therapeutics 2011 Annual Meeting

    Google Scholar 

  35. Gupta M, LoRusso PM, Wang B et al (2012) Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab-DM1, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharm 52(5):691–703

    Article  CAS  Google Scholar 

  36. Hurvitz SA, Dirix L, Kocsis J et al (2011) Trastuzumab emtansine (T-DM1) versus trastuzumab  +  docetaxel in previously untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450g/BO21976). ESMO Annual Meeting. Abstract 5001

    Google Scholar 

  37. Kirkova J, Davis MP, Walsh D et al (2006) Cancer symptom assessment instruments: a systematic review. J Clin Oncol 24:1459–1473

    Article  PubMed  Google Scholar 

  38. Baselga J et al (2010) First results of the NeoALTTO trial (BIG 01–06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. SABCS 2010. Abstract 291

    Google Scholar 

  39. Gianni L, et al (2010) Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (NeoSphere). SABCS 2010. Abstract S3-2.

    Google Scholar 

  40. Bang Y-J, Cutsem EV, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 376:687–697

    Article  PubMed  CAS  Google Scholar 

  41. Nishiyama M, Eguchi H (2009) Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy. Adv Drug Deliv Rev 61:402–407

    Article  PubMed  CAS  Google Scholar 

  42. Berns K, Horlings HM, Hennessy BT et al (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395–402

    Article  PubMed  CAS  Google Scholar 

  43. Scaltriti M, Rojo F, Ocana A et al (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. JNCI 99:628–638

    Article  PubMed  CAS  Google Scholar 

  44. Verma S et al (2012) Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med

    Article  PubMed  CAS  Google Scholar 

  45. Bender BC et al (2012) A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol

    Article  PubMed  CAS  Google Scholar 

  46. Baselga J et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast ­cancer. N Engl J Med 366(2):109–119

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Helen Diller Family Comprehensive Cancer Center, H.S.R., University of California San Francisco, San Francisco, CA, USA

    Hope S. Rugo

  2. I.E.K., Dana Farber Cancer Institute, Boston, MA, USA

    Ian E. Krop

  3. Y-W.C., Exploratory Clinical Development, Genentech, Inc., South San Francisco, CA, USA

    Yu-Waye Chu

Authors
  1. Hope S. Rugo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ian E. Krop
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yu-Waye Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hope S. Rugo .

Editor information

Editors and Affiliations

  1. DNA Way 1, South San Francisco, 94080, California, USA

    Gail Lewis Phillips

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Rugo, H.S., Krop, I.E., Chu, YW. (2013). Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer with a Focus on Breast Cancer. In: Phillips, G. (eds) Antibody-Drug Conjugates and Immunotoxins. Cancer Drug Discovery and Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5456-4_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5456-4_11

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5455-7

  • Online ISBN: 978-1-4614-5456-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation